Herranz Amo F, Díez Cordero J M, Verdú Tartajo F, Bielsa Carrillo A, García Burgos J, Subirá Ríos D, Castaño González I
Servicio de Urología, Hospital General Universitario Gregorio Marañón, Madrid, España.
Arch Esp Urol. 2000 Sep;53(7):619-24.
To analyze retrospectively the efficacy of radical cystectomy alone in the treatment of transitional cell carcinoma of the bladder.
125 patients who underwent radical cystectomy were evaluated. The mean follow-up was 62 months. At the time of the study, 65 patients were alive (3 with bladder tumor and 1 with a second primary) and 60 patients had died (50 from bladder cancer and 10 from other causes). Nine patients were lost to follow-up. The Kaplan-Meier method was used for the survival analysis and the log-rank test for the comparison of the variables.
The overall survival at 5 years was 50% and the cancer-specific survival was 56%. By tumor stage, the cancer-specific survival at 3 and 5 years were respectively: 83% and 85% for pT1, 78% and 70% for pT2, 52% and 42% for pT3, 24% and 12% for pT4 and 14% for pN+ (p < 0.0001). No differences were found between stages pT2a (73% and 68%) and pT2b (71% and 53%) (p = 0.2). The survival was significantly higher in patients with no residual tumor in the cystectomy specimen (pT0) (93% and 83%) than in those with residual tumor (60% and 53%) (p = 0.03).
Radical cystectomy alone in the treatment of transitional cell carcinoma of the bladder was found to be effective in patients with tumor stage pT2. It is less effective in patients with tumor in the advanced stages (pT3 or pT4) or lymph node invasion. Radical cystectomy is an overtreatment in patients with no residual tumor in the cystectomy specimen.
回顾性分析单纯根治性膀胱切除术治疗膀胱移行细胞癌的疗效。
对125例行根治性膀胱切除术的患者进行评估。平均随访时间为62个月。在研究时,65例患者存活(3例有膀胱肿瘤,1例有第二原发性肿瘤),60例患者死亡(50例死于膀胱癌,10例死于其他原因)。9例患者失访。采用Kaplan-Meier法进行生存分析,采用对数秩检验比较变量。
5年总生存率为50%,癌症特异性生存率为56%。按肿瘤分期,3年和5年的癌症特异性生存率分别为:pT1期为83%和85%,pT2期为78%和70%,pT3期为52%和42%,pT4期为24%和12%,pN+期为14%(p<0.0001)。pT2a期(73%和68%)和pT2b期(71%和53%)之间未发现差异(p=0.2)。膀胱切除标本无残留肿瘤(pT0)的患者生存率(93%和83%)显著高于有残留肿瘤的患者(60%和53%)(p=0.03)。
单纯根治性膀胱切除术治疗膀胱移行细胞癌对pT2期肿瘤患者有效。对晚期(pT3或pT4)肿瘤或有淋巴结转移的患者效果较差。膀胱切除标本无残留肿瘤的患者,根治性膀胱切除术属于过度治疗。